Tazarotene - Moligand™, 10mM in DMSO , Retinoic acid receptor agonist, CAS No.118292-40-3, Retinoic acid receptor agonist

CAS: 118292-40-3 Cat. No.: T408686 Peso molecular: 351.46 Número EC: 601-516-4 PubChem CID: 5381

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

AGN190168 | 6-​[2-​(3,​4-​dihydro-​4,​4-​dimethyl-​2H-​1-​benzothiopyran-​6-​yl)​ethynyl]​-​3-​Pyridinecarboxylic acid ethyl ester

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

Tazarotene Tazarotene (AGN190168) is a retinoid prodrug of tazarotenic acid, which is a RAR agonist, used to treat psoriasis, acne, and sun damaged skin.
In vitro

Tazarotene causes ERK activation, RB tumor suppressor protein hypophosphorylation, G0 arrest, and myeloid differentiation in HL-60 human myeloblastic leukemia cells. Tazarotene could propel either early or late portions of the period leading to differentiation and G0 arrest and is interchangeable with an RARalpha-selective ligand. Tazarotene therapy regulates gene transcription via interaction with specific nuclear retinoic acid receptors (RARs), thereby modulating the three key pathogenic factors in psoriasis. Tazarotene inhibits the proliferation of fibroblasts and synthesis of DNA and collagen. Tazarotene down-regulates markers of keratinocyte differentiation, keratinocyte proliferation, and inflammation. Tazarotene also up-regulates three novel genes TIG-1 (tazarotene-induced gene-1), TIG-2, and TIG-3, which may mediate an antiproliferative effect. Tazarotene causes growth suppression in retinoid-responsive breast cancer cell lines by up-regulating TIG3.

In vivo

Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in UV-treated Ptch1+/− mice. Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in ionizing radiation-treated Ptch1+/− mice.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥98%

Specifications

Sinónimos

AGN190168 | 6-​[2-​(3, ​4-​dihydro-​4, ​4-​dimethyl-​2H-​1-​benzothiopyran-​6-​yl)​ethynyl]​-​3-​Pyridinecarboxylic acid ethyl ester

Especificaciones y pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos y fisiológicos

Tazarotene (AGN190168) is a retinoid prodrug of tazarotenic acid, which is a RAR agonist, used to treat psoriasis, acne, and sun damaged skin.

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

AGONIST

Mecanismo de acción

Retinoic acid receptor agonist

Propiedades del producto

• ALogP: 4.9

Nombres e identificadores

• Isómeros SMILES: CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
• WGK Alemania: 3
• RTECS: US5675100
• PubChem CID: 5381
• Peso molecular: 351.46
• Reaxy-Rn: 8159145

Objetivos asociados (humanos)

RARG Tclin Retinoic acid receptor gamma (2 Activities)

Discover Target: RARG

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

RARB Tclin Retinoic acid receptor beta (2 Activities)

Discover Target: RARB

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

RARA Tclin Retinoic acid receptor alpha (2 Activities)

Discover Target: RARA

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Propiedades químicas y físicas

• Punto de fusión (°C): 105 °C

Referencias

1. Yan Deng, Hao Cheng, Ji Zhu, Yue Jiang, Hongwu Sun, Guocheng Li, Jing Wei, Ruoyi Xue, Rang Feng, Jingwen Cao, Wenkang Yu, Yalan Wang, Mingqi Xu, Quanming Zou, Haibo Li.  (2025)  Tamibarotene-Loaded Nanoemulsion Incorporating Toll-like Receptor 2/6 Agonist as an Intramuscular Adjuvant System Enhances Gastrointestinal Mucosal Immunity.  ACS Nano,      [PMID:40376869] [10.1021/acsnano.5c00563]